Abstract Library

#4654 Usefulness of soluble tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors R2 and R3 in progression assessment of gastroenteropancreatic neuroendocrine neoplasms – A preliminary study

Introduction: TRAIL is a member of TNF family and appears in membrane and soluble (s) forms. It acts either triggering (R1 and R2) or blocking (R3 and R4) apoptosis. TRAIL targeted therapy is widely studied and known as potentially effective in number of neoplasms.

Conference:

Presenting Author: Kaczmarska-Turek D

Authors: Kaczmarska-Turek D, Radziszewski M, Matałowski M, Liszcz A, Bartoszewicz Z,

Keywords: gastroenteropancreatic neuroendocrine neoplasm, tumour necrosis factor-related apoptosis-inducing ligand, tumour progression, PRRT, TRAIL, GEP-NEN,

#4645 Radio-guided surgery in use for treatment of early relapse in small intestine neuroendocrine tumours

Introduction: Surgery is the only definitive therapy for neuroendocrine tumours (NET). In number of small intestine NET first symptom is ileus or perforation, lifesaving surgical procedures applied. Such cases have significant risk of recurrence.

Conference:

Presenting Author: Hajac �

Authors: Hajac L, Szewczyk K, Piwkowski P, Chowaniec Z, Mazurak J,

Keywords: radio guided surgery, Neuroendocrine tumour, early relapse,

#4481 Predicting peptide receptor radionuclide therapy (PRRT) response through the landscape of the immune microenvironment in neuroendocrine tumours

Introduction: Neuroendocrine tumours (NETs) often have poor prognosis upon metastasis. Peptide receptor radionuclide therapy (PRRT) is a novel treatment leveraging targeted cytotoxicity of radionuclides to efficiently address primary and metastatic tumours of NETs.

Conference:

Presenting Author: Yu J

Authors: Zeng Z, Lu M, Xie Q, Li J, Yang Z,

Keywords: peptide receptor radionuclide therapy, neuroendocrine tumour, tumour immune microenvironment, tumour response, therapeutic effect prediction,

#4398 The role of chromogranin A as a biomarker in neuroendocrine tumours: Diagnostic and prognostic implications

Introduction: Chromogranin A (CgA) is a widely used serum biomarker for neuroendocrine tumours (NETs), reflecting tumour burden and secretory activity. Despite its clinical utility, the diagnostic sensitivity and prognostic value of CgA remain a subject of debate, especially given its potential for false positives and its variation across different NET subtypes.

Conference:

Presenting Author:

Authors: Xu L, Ye M, Zeng X, Chen S, Ding Y,

Keywords: Chromogranin A, neuroendocrine tumour, diagnosis, prognosis, biomarker, Ki-67, metastatic disease,

#4313 Identification of gastroenteropancreatic neuroendocrine tumour patients with high liver tumour burden based on clinicopathological features

Introduction: Metastatic liver tumour burden (LTB) is a prognostic factor affecting the survival of gastroenteropancreatic neuroendocrine tumours (GEP-NETs), but evaluation of the LTB usually depends on radiologic and functional imaging.

Conference:

Presenting Author:

Authors: Jumai N, Chen L, Liu M, He Q, Zeng Z,

Keywords: liver tumour burden, prognosis, GEP-NET,